| |
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about the latest innovations in packaging and aseptic filling solutions that meet the complex demands of emerging therapies. Discover how to ensure product integrity, safety and efficiency. Register now. 
|
|
Today’s Big NewsJan 13, 2025 |
|
Connecting the Innovation Districts in Cincinnati, Columbus and Cleveland, the Ohio Discovery Corridor drives opportunity, innovation, and collaboration unlike anywhere else in the Midwest. Explore the corridor. 
|
|
| By Ben Adams,James Waldron,Gabrielle Masson,Darren Incorvaia It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the year. |
|
|
|
By Nick Paul Taylor Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics’ PI3Kα pipeline for up to $2.5 billion. |
By Gabrielle Masson In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. |
By Ben Adams Gilead continues its divergence out of its original infectious disease beginnings and into cancer and, now, more deeply than before, into inflammation, penning a major $1.7 billion deal with dermatology specialist Leo Pharma just a few days before the J.P. Morgan Healthcare Conference. |
|
A lack of data keeps you from ensuring relevancy and quality, calling results into question. View case studies and learn about utilizing basic data to help ensure the accuracy of your research. Read More >> 
|
|
By James Waldron T-cell engagers have been hot property in recent months, so it’s only right that one of the biggest deals to kick off the J.P. Morgan Healthcare conference should see AbbVie expand its interest in the tech. |
By Kevin Dunleavy Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s closing price of Intra-Cellular, a New York City based biotech that develops and markets products for the central nervous system. |
By Angus Liu About 100 days into the CEO role at Kyverna Therapeutics, Warner Biddle has identified stiff person syndrome, a rare neurological disorder launched into public attention by Céline Dion’s diagnosis, as the biotech’s gateway to delivering the first approved CAR-T therapy in an autoimmune disease. |
By Gabrielle Masson Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell therapy in the neurodegenerative disease. |
By Fraiser Kansteiner,Zoey Becker,Angus Liu,Kevin Dunleavy,Eric Sagonowsky While the overall volume of pharma and life sciences M&A activity was healthy in 2024 versus historic levels, deals trended toward the smaller side, reducing the total deal value observed for the year. That inclination for large pharma companies to pursue small and mid-sized transactions is likely to persist in 2025, too, analysts at Leerink Partners and PwC have opined. |
By James Waldron Investors clearly appreciate the song that Tune Therapeutics is singing, handing over $175 million in series B funds as the biotech takes its epigenetic silencing drug into the clinic. |
By Eric Sagonowsky Having witnessed a 90%-plus stock price slide during recent years, Sage Therapeutics’ leadership must decide whether now is the right time to accept a buyout offer. |
By James Waldron Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with similar preclinical breast cancer-focused therapies. |
By James Waldron Telix Pharmaceuticals’ expansion phase shows no sign of running out yet, with the Australian radiopharma company paying $45 million in upfront cash and equity for a pipeline of preclinical cancer antibodies and a Californian research facility. |
By Nick Paul Taylor Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes can muscle in on the market. Kailera and partner Jiangsu Hengrui Pharmaceuticals linked the injectable GLP-1/GIP receptor dual agonist to 22.8% mean weight loss after 36 weeks. |
By Darren Incorvaia A new company is making its debut with a series A sum that’s sure to make hearts race. Launching with $300 million in hand, Kardigan plans to develop parallel treatments to prevent and cure cardiovascular diseases so that they’re no longer the leading cause of death worldwide, the company announced in a Jan. 10 release. |
By Gabrielle Masson Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. |
By Fraiser Kansteiner Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. Late this week, a quartet of companies—IGM Biosciences, Y-mAbs Therapeutics, Passage Bio and Shoreline Biosciences—each revealed plans to cut jobs as they rework their respective pipelines and business structures. |
By Fraiser Kansteiner,Angus Liu,Ben Adams,Kevin Dunleavy,Zoey Becker,Eric Sagonowsky For the 43rd edition of the JPM conference, Johnson & Johnson stole the spotlight off the bat. But plenty of other company updates are on deck for day 1. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we dive into 2024's batch of new FDA drug approvals, highlighting some potential blockbusters and shifts from previous years' lists. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
